TRX-103
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 36 patients (estimated)
- Sponsors
- Tr1X, Inc.
- Tags
- T Cell (Allogeneic), Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1919
- NCT Identifier
- NCT06462365
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.